報價延遲最少15分鐘:2024/11/01 01:22 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
52.88 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
1.68/4.34
|
|
企業價值
150.09B
|
| 資產負債 |
|
每股賬面淨值
32.28
|
| 現金流量 |
|
現金流量率
0.07
|
| 損益表 |
|
收益
36.22B
|
|
每股收益
19.30
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/11/01 01:22 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolicarea will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue. |